• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Core Laboratories Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    5/27/25 4:27:11 PM ET
    $CLB
    Oilfield Services/Equipment
    Energy
    Get the next $CLB alert in real time by email
    8-K
    0001958086false00-000000000019580862025-05-212025-05-21

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 21, 2025

    CORE LABORATORIES INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    001-41695

    Not Applicable

    (State or Other Jurisdiction

    of Incorporation)

    (Commission File Number)

    (IRS Employer

    Identification No.)

     

     

     

    6316 Windfern Road

    Houston, TX

    77040

    (Address of Principal Executive Offices)

    (Zip Code)

    Registrant’s Telephone Number, Including Area Code: (713) 328-2673

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange on which registered

    Common Stock (par value $0.01)

     

    CLB

     

    New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

    Core Laboratories Inc. (the “Company”) held its Annual Meeting of Shareholders (the “Annual Meeting”) on May 21, 2025 in Houston, Texas. At the Annual Meeting, the Company’s shareholders were asked to vote on the following proposals: (1) to elect one new Class II Director and to re-elect two current Class II Directors to serve under the terms and conditions described within the Company’s proxy statement until it’s annual meeting in 2028 and until their successors shall have been duly elected and qualified; (2) to ratify the appointment of KPMG LLP (“KPMG”) as the Company’s independent registered public accountant for the year ending December 31, 2025; and (3) to approve, on an advisory basis, the compensation philosophy, policies and procedures described in the section of the Company’s proxy statement entitled Compensation Discussion and Analysis (“CD&A”), and the compensation of the Company’s named executive officers as disclosed pursuant to the U.S. Securities and Exchange Commission’s compensation disclosure rules, including the compensation tables.

    Given that more than 50% of the issued share capital was present and represented at the Annual Meeting either in person or by proxy, proposal 1 could be approved by the affirmative vote of a plurality of votes cast, proposal 2 could be approved by the affirmative vote of an absolute majority of 50% + 1 of shares present and entitled to vote, and proposal 3 could be approved by the affirmative vote of a 66-2/3% majority of shares present and entitled to vote. All items were approved, and the certified results of the matters voted upon at the Annual Meeting are as follows:

    Proposal 1 – Election of Class II Directors: The election of each Class II director was approved as follows:

    Nominee

     

    For

     

    Withheld

     

    Broker Non-Votes

    Martha Z. Carnes

     

    37,510,862

     

    2,818,729

     

    2,182,232

    Katherine Murray

     

    39,747,197

     

    582,394

     

    2,182,232

    Rob Martinovich

     

    38,894,796

     

    1,434,795

     

    2,182,232

    Proposal 2 – Appointment of KPMG as Independent Registered Public Accountant: The ratification of the appointment of KPMG as the Company’s independent registered public accountant for the fiscal year ending December 31, 2025, was approved as follows:

    For

     

    Against

     

    Abstentions

     

    Broker Non-Votes

    41,812,461

     

    685,311

     

    14,051

     

    —

    Proposal 3 – Approving the Compensation of the Company’s Named Executive Officers: An advisory vote on the compensation of the Company’s named executive officers was approved as follows:

    For

     

    Against

     

    Abstentions

     

    Broker Non-Votes

    38,010,404

     

    2,292,675

     

    26,512

     

    2,182,232

     

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

     

     

     

     

     

     

     

    Core Laboratories Inc.

     

     

     

     

     

     

     

    Dated: May 27, 2025

     

    By

     

    /s/ Christopher S. Hill

     

     

     

     

     

     

    Christopher S. Hill

     

     

     

     

     

     

    Chief Financial Officer

     

     

     

     


    Get the next $CLB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLB

    DatePrice TargetRatingAnalyst
    3/12/2025$15.00 → $16.00Sell → Neutral
    Citigroup
    6/30/2023$22.00 → $21.00Neutral → Sell
    Citigroup
    4/18/2023$21.50Neutral → Underperform
    BofA Securities
    1/9/2023Underperform → Neutral
    BofA Securities
    10/7/2022$24.00 → $17.00Sell → Neutral
    Citigroup
    9/26/2022$20.00Equal-Weight → Underweight
    Morgan Stanley
    4/18/2022$19.50 → $21.30Neutral → Underweight
    Piper Sandler
    1/18/2022$32.00 → $30.00Equal-Weight
    Morgan Stanley
    More analyst ratings